Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases

Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Alcaide, Julia, Delgado, Mayte, Legerén, Marta, Jurado, José Miguel, Blancas, Isabel, Pereda, Teresa, López, Jorge, Garrido, Margarita, Sánchez, María J., García, José L., Rueda, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103908/
https://www.ncbi.nlm.nih.gov/pubmed/27899972
http://dx.doi.org/10.3892/ol.2016.5068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103908/
https://www.ncbi.nlm.nih.gov/pubmed/27899972
http://dx.doi.org/10.3892/ol.2016.5068

Ejemplares similares